Jeremy Wright, DO
Nephrology · Lewiston, MENPI 1265870968
Payments from drug & device makers
What this record shows
Fresenius USA Marketing, Inc. accounts for 80.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $588 and has fallen 93.7% since, to $37 in 2024.
Across 11 payments — averaging $64.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$570
- Otsuka America Pharmaceutical, Inc.$37
- Outset Medical Inc$29
- Vifor Pharma, Inc.$27
- Mallinckrodt Enterprises LLC$18
- Nxstage Medical, Inc.$15
- plus $12 from 1 others
What the payments were for
- Travel & lodging$37954%
- Food & beverage$32946%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 4 | $570 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Outset Medical Inc | 1 | $29 |
| Vifor Pharma, Inc. | 1 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Nxstage Medical, Inc. | 1 | $15 |
| AstraZeneca | 1 | $12 |
How this compares
$708 in reported general payments places this provider in the 85th percentile of 42 nephrology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 154 | $234,172 |
| FarxigaDapagliflozin Propanediol | 76 | $88,628 |
| VelphoroSucroferric Oxyhydroxide | 13 | $23,707 |
| Potassium Chloride | 43 | $4,158 |
| Eplerenone | 31 | $3,591 |
| Calcitriol | 231 | $3,179 |
| Potassium Citrate ErPotassium Citrate | 21 | $2,459 |
| Desmopressin Acetate | 13 | $2,084 |
| Sevelamer Carbonate | 11 | $1,332 |
| Midodrine Hcl | 16 | $1,311 |
| Losartan Potassium | 91 | $852 |
| Amlodipine Besylate | 126 | $837 |
| Bumetanide | 23 | $710 |
| Lisinopril | 99 | $634 |
| Torsemide | 23 | $622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $12 | $88,62876 claims |
| Fresenius USA Marketing, Inc.Velphoro | $570 | $23,70713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 42 nephrology providers in Maine.
Other nephrology in Lewiston
- Cynthia DesoiLewiston$129
- Matthew PyentaLewiston$94
- Andrew ThorntonLewiston$48
- Jenie SmithLewiston$17
- Ioan CosmaPortland$4K
- Abd Assalam QannusPortland$3K
- Robert IsomPortland$2K
- Faisal JamalBelfast$855
- Alan SegalPortland$783
- Sean HebertPortland$689
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.